News | October 16, 2025
Syngene International invests in peptide laboratory in Bengaluru
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Subscribe To Our Newsletter & Stay Updated
